Novonesis will invest €600 million to expand its Patalganga site in India and build a new enzyme production facility, adding manufacturing capacity for customers across biofuels, household care, food and beverages, and other biosolutions markets. The expanded operation is expected to be fully operational in 2030 and will form part of the company’s wider effort to increase the flexibility and resilience of its international production network.
The scale of the investment makes Patalganga one of the more significant additions to Novonesis’ current manufacturing programme. The company describes the planned facility as one of the world’s most advanced enzyme production operations, but the more important industrial point is its location. Additional capacity will be placed closer to customers across India, the Middle East, and Africa, markets that Novonesis expects to grow faster than developed economies over the coming years.
That geographic shift matters for a business supplying biological process technologies into several very different industries. Enzymes used in biofuel production, detergent formulations, food processing, and other applications may share biological origins, but customer requirements, product specifications, production campaigns, and demand cycles vary considerably. The new plant will therefore need to provide more than additional nominal capacity; it must give Novonesis enough manufacturing flexibility to serve a diverse regional customer base without weakening consistency across its global network.
Industrial enzyme production relies on tightly controlled biological manufacturing, with fermentation and downstream processing supported by utilities, cleaning systems, quality laboratories, process control, and material handling. Increasing output consequently involves considerably more than adding fermentation vessels. New capacity must be integrated with the systems that maintain controlled conditions from inoculation through separation, formulation, and final release, while protecting production from contamination and process deviations that can disrupt an entire batch.
Novonesis is also expanding that network elsewhere. The company identifies recent capacity programmes at Rayong in Thailand, Franklinton in North Carolina, Taicang in China, Araucaria in Brazil, and West Allis in Wisconsin. Patalganga therefore sits inside a broader manufacturing strategy intended to distribute production more effectively across regions and improve supply flexibility rather than concentrating future growth into one location.
That approach can improve resilience, although it also creates a demanding standardisation problem. Biological manufacturing must deliver comparable performance from facilities operating with different equipment, workforces, utility systems, and local supply chains. Strains, process conditions, quality controls, and finished-product specifications have to remain tightly managed if production is to move or expand across the network without creating unnecessary qualification work for customers.
The Indian facility will also incorporate measures intended to reduce utility demand as capacity increases. Novonesis says freshwater recycling will reduce the amount of water drawn by the site, while integrated heat pumps will lower the energy required for operation. Together, those measures are intended to put the facility on a path towards lower Scope 1 and Scope 2 emissions.
Water and heat are material engineering considerations for fermentation-based production. Large biological processes require controlled temperatures and substantial cleaning, while downstream stages can add further heating, cooling, and separation loads. Expanding output without improving those utility systems would risk increasing energy and water demand broadly in line with production. The Patalganga design is intended to weaken that relationship by building efficiency into the expansion rather than treating it as a later retrofit.
The investment also shows the increasingly conventional industrial infrastructure behind the growth of biosolutions. Enzymes may be marketed around biological performance, lower process temperatures, improved yield, or reduced chemical use, but manufacturing them at scale still requires process vessels, pumps, pipework, instrumentation, filtration, utilities, automation, laboratories, and skilled operators. Growth in industrial biotechnology therefore translates directly into demand for capital-intensive production engineering.
For customers, regional manufacturing can also reduce dependence on long international supply routes. Enzymes are typically used in relatively small quantities compared with bulk raw materials, but they may be essential to the efficiency or performance of a production process. A shortage can consequently have an impact out of proportion to the physical volume involved. Bringing more capacity closer to growing markets gives Novonesis another option for balancing demand when individual sites or transport routes are disrupted.
The company says the expansion fits within previously communicated capital expenditure plans, meaning the €600 million programme is part of an established investment strategy rather than a sudden change in financial direction. Novonesis president and chief executive Ester Baiget has linked the project to long-term growth, while chief operating officer Anders Lund has emphasised scale, operational resilience, efficiency, and supply flexibility.
Those objectives will ultimately be tested through plant utilisation rather than the announcement itself. Patalganga is not expected to reach full operation until 2030, leaving several years of engineering, construction, equipment installation, qualification, and commissioning ahead. The product mix required by customers at that point will almost certainly differ from today’s exact forecasts, so manufacturing flexibility will be as important as headline output.
A €600 million commitment gives Novonesis considerable new production capability in one of its target growth regions. The more difficult measure will come after commissioning: whether the plant can absorb changing demand across several industries while delivering the expected quality, water, energy, and supply-chain performance. Fermentation capacity is expensive to build. Keeping it reliably productive across a changing product portfolio is where the investment case will be proved.
